Skip to main content

Table 3 The evaluation of the parameters associated with AEs in CART therapy

From: Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience

paremeters

witn AEs

without AEs

p-value

Age (n = 233)

  ≤ 60 years old

12

110

1.000

  ≥ 61 years old

10

101

Sex (n = 233)

 male

16

147

1.000

 female

6

64

Appearance of havested ascites (n = 233)

 bloody

4

41

0.390

 chylous

0

20

 serous

18

150

Classificarion of havested ascites (n = 233)

 exudative ascites

16

126

0.261

 transudative ascites

6

85

Weight of havested ascites (n = 233)

  ≤ 4,720 g

7

110

0.051

  ≥ 4,721 g

15

101

Weight of concentrated ascites (n = 233)

  ≤ 490 g

8

110

0.183

  ≥ 491 g

14

101

Processing rate of ascites (n = 233)

  ≤ 89 mL/min

14

105

0.265

  ≥ 90 mL/min

8

106

Volume of saline used for washing filter membrane (n = 225)

  ≤ 450 mL

8

107

0.250

  ≥ 451 mL

13

97

Amount of calculated total protein for reinfusion (n = 233)

  ≤ 64.0 g

7

110

0.051

  ≥ 64.1 g

15

101

Amount of calculated albumin for reinfusion (n = 233)

  ≤ 32.6 g

7

111

0.075

  ≥ 32.7 g

15

100

Prophylaxis for AE (n = 233)

 Steroidsa

20

180

0.748

 other than steroidsb

2

31

Administration rate (n = 228)

  ≤ 100 mL/h

10

181

 < 0.001

  ≥ 125 mL/h

12

25

Reinfusion speed of protein (n = 228)

  ≤ 10.8 g/h

3

109

 < 0.001

  ≥ 10.9 g/h

19

97

Administration rate in cases treated with steroidsa (n = 196)

  ≤ 100 mL/h

10

156

 < 0.001

  ≥ 125 mL/h

10

20

Reinfusion speed of proteinin cases treated with steroidsa (n = 196)

  ≤ 10.8 g/h

3

98

 < 0.001

  ≥ 10.9 g/h

17

78

  1. AE adverse effects, CART cell-free and concentrated ascites reinfusion therapy
  2. aequivalent to ≥ 100 mg hydrocortisone
  3. bnon-steroidal anti-inflammatory drugs, antihistamines, no prophylaxis, etc.